Posted by Michael Wonder on 25 Jan 2016
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) regimen receives expanded FDA approval in unresectable or metastatic melanoma across BRAF status
23 January 2016 - This indication is approved under accelerated approval based on progression-free survival.
For more details, go to: http://news.bms.com/press-release/bmy/bristol-myers-squibbs-opdivo-nivolumab-yervoy-ipilimumab-regimen-receives-expandedhttp://news.bms.com/press-release/bmy/bristol-myers-squibbs-opdivo-nivolumab-yervoy-ipilimumab-regimen-receives-expanded
